- Home
- GCBC vs ACRS Comparison
GCBC vs ACRS Comparison
Compare GCBC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCBC | ACRS |
|---|---|---|
| Founded | 1889 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.0M | 529.9M |
| IPO Year | 1998 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GCBC | ACRS |
|---|---|---|
| Price | $35.30 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $10.18 |
| AVG Volume (30 Days) | 19.1K | ★ 3.6M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | 31.69 | ★ 69.01 |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $4,117,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.78 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $21.38 | $2.10 |
| 52 Week High | $37.25 | $6.60 |
Technical Indicators
Market Signals| Indicator | GCBC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 40.23 |
| Support Level | $33.55 | $3.18 |
| Resistance Level | $35.84 | $3.86 |
| Average True Range (ATR) | 0.78 | 0.27 |
| MACD | 0.20 | 0.08 |
| Stochastic Oscillator | 60.26 | 74.94 |
Price Performance
Historical ComparisonAbout GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.